Electromedical Technologies, Inc. (OTC: EMED) Provides Mid-Year Update Highlighting Financial Restructuring, Regulatory Alignment, and Strategic Progress
Electromedical Technologies (OTC: EMED), a developer of FDA-cleared electrotherapy devices for pain management, has released a mid-year update outlining significant restructuring initiatives. The company has finalized an agreement with its largest convertible noteholder to retire their position, reducing potential dilution.
EMED has voluntarily suspended SEC reporting obligations by filing Form 15, while maintaining OTC Markets compliance and 15c2-11 quotation status. The company plans to resume full SEC reporting within the allowed timeframe.
Upcoming announcements include new board appointments, distribution agreements in healthcare and consumer sectors, preliminary purchase orders, WellnessPro Infinity鈩� device updates, and expanded strategic partnerships.
Electromedical Technologies (OTC: EMED), sviluppatore di dispositivi elettroterapici approvati dalla FDA per la gestione del dolore, ha pubblicato un aggiornamento di met脿 anno che illustra importanti iniziative di ristrutturazione. L'azienda ha finalizzato un accordo con il suo maggiore detentore di note convertibili per ritirare la loro posizione, riducendo cos矛 la possibile diluizione.
EMED ha volontariamente sospeso gli obblighi di rendicontazione alla SEC presentando il Modulo 15, mantenendo per貌 la conformit脿 ai mercati OTC e lo stato di quotazione secondo la regola 15c2-11. La societ脿 prevede di riprendere la piena rendicontazione alla SEC entro i termini consentiti.
Tra gli annunci imminenti figurano nuove nomine nel consiglio di amministrazione, accordi di distribuzione nei settori sanitario e consumer, ordini di acquisto preliminari, aggiornamenti sul dispositivo WellnessPro Infinity鈩� e l'espansione di partnership strategiche.
Electromedical Technologies (OTC: EMED), desarrollador de dispositivos de electroterapia aprobados por la FDA para el manejo del dolor, ha publicado una actualizaci贸n de mitad de a帽o que detalla importantes iniciativas de reestructuraci贸n. La empresa ha finalizado un acuerdo con su mayor tenedor de notas convertibles para retirar su posici贸n, reduciendo as铆 la posible diluci贸n.
EMED ha suspendido voluntariamente las obligaciones de reporte ante la SEC presentando el Formulario 15, manteniendo el cumplimiento con los mercados OTC y el estatus de cotizaci贸n bajo la regla 15c2-11. La compa帽铆a planea reanudar el reporte completo ante la SEC dentro del plazo permitido.
Los pr贸ximos anuncios incluyen nuevas designaciones en la junta directiva, acuerdos de distribuci贸n en los sectores de salud y consumo, 贸rdenes de compra preliminares, actualizaciones del dispositivo WellnessPro Infinity鈩� y la expansi贸n de alianzas estrat茅gicas.
Electromedical Technologies (OTC: EMED)電� FDA 鞀轨澑 韱奠 甏�毽� 鞝勱赴旃橂旮瓣赴毳� 臧滊皽頃橂姅 須岇偓搿�, 欷戧皠 鞐半弰 鞐呺嵃鞚错姼毳� 韱淀暣 欷戩殧頃� 甑“ 臁办爼 瓿勴殟鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 斓滊寑 鞝勴櫂靷眲 氤挫湢鞛愳檧鞚� 瓿勳暯鞚� 斓滌 頇曥爼頃橃棳 頃措嫻 歆�攵勳潉 須岇垬頃溂搿滌崹 頋劃 臧�電レ劚鞚� 欷勳榾鞀惦媹雼�.
EMED電� Form 15毳� 鞝滌稖頃橃棳 SEC 氤搓碃 鞚橂毳� 鞛愲皽鞝侅溂搿� 欷戨嫧頄堨溂氅�, OTC 鞁滌灔 欷�靾� 氚� 15c2-11 靸侅灔 靸來儨電� 鞙犾頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 項堨毄霅� 旮瓣皠 雮挫棎 鞕勳爠頃� SEC 氤搓碃毳� 鞛皽頃� 瓿勴殟鞛呺媹雼�.
鞎烄溂搿� 氚滍憸霅� 雮挫毄鞐愲姅 靸堧鞖� 鞚挫偓須� 鞛勲獏, 鞚橂 氚� 靻岆箘鞛� 攵�氍胳潣 鞙犿喌 瓿勳暯, 鞓堧箘 甑Г 欤茧, WellnessPro Infinity鈩� 旮瓣赴 鞐呺嵃鞚错姼, 攴鸽Μ瓿� 鞝勲灥鞝� 韺岉姼雱堨嫮 頇曤寑臧� 韽暔霅╇媹雼�.
Electromedical Technologies (OTC : EMED), d茅veloppeur d'appareils d'茅lectroth茅rapie approuv茅s par la FDA pour la gestion de la douleur, a publi茅 une mise 脿 jour 脿 mi-ann茅e d茅taillant d'importantes initiatives de restructuration. La soci茅t茅 a finalis茅 un accord avec son principal d茅tenteur de billets convertibles pour racheter leur position, r茅duisant ainsi la dilution potentielle.
EMED a volontairement suspendu ses obligations de d茅claration aupr猫s de la SEC en d茅posant le formulaire 15, tout en maintenant sa conformit茅 aux march茅s OTC et son statut de cotation 15c2-11. La soci茅t茅 pr茅voit de reprendre la d茅claration compl猫te 脿 la SEC dans les d茅lais autoris茅s.
Les annonces 脿 venir incluent de nouvelles nominations au conseil d'administration, des accords de distribution dans les secteurs de la sant茅 et de la consommation, des commandes d'achat pr茅liminaires, des mises 脿 jour sur l'appareil WellnessPro Infinity鈩� et l'expansion de partenariats strat茅giques.
Electromedical Technologies (OTC: EMED), ein Entwickler von von der FDA zugelassenen Elektrotherapieger盲ten zur Schmerzbehandlung, hat ein Zwischenjahres-Update ver枚ffentlicht, das bedeutende Restrukturierungsma脽nahmen beschreibt. Das Unternehmen hat eine Vereinbarung mit seinem gr枚脽ten Inhaber wandelbarer Schuldverschreibungen abgeschlossen, um deren Position zur眉ckzukaufen und so eine m枚gliche Verw盲sserung zu verringern.
EMED hat freiwillig die Meldepflichten bei der SEC durch Einreichung des Formulars 15 ausgesetzt, w盲hrend es die Compliance mit den OTC-M盲rkten und den 15c2-11-Quotierungsstatus beibeh盲lt. Das Unternehmen plant, die vollst盲ndige SEC-Berichterstattung innerhalb des erlaubten Zeitrahmens wieder aufzunehmen.
Kommende Ank眉ndigungen umfassen neue Vorstandsbestellungen, Vertriebsvereinbarungen im Gesundheits- und Konsumbereich, vorl盲ufige Bestellungen, Updates zum WellnessPro Infinity鈩� Ger盲t und erweiterte strategische Partnerschaften.
- Agreement with largest convertible noteholder to retire position, reducing dilution risk
- Preliminary purchase orders secured from wellness-sector organizations
- Maintained OTC Markets compliance and 15c2-11 quotation status
- Upcoming expansion of distribution networks in healthcare and consumer sectors
- Voluntary suspension of SEC reporting obligations through Form 15 filing
- Ongoing settlement discussions with remaining noteholders indicate continued debt concerns
- Financial restructuring efforts suggest current capital structure challenges
Electromedical Technologies (OTC: EMED) outlines key financial restructuring milestones, upcoming product updates, and new strategic partnerships to drive sustainable growth in the pain management market.
SCOTTSDALE, ARIZONA / / August 6, 2025 / ("Electromedical" or the "Company") (), a developer and manufacturer of FDA-cleared electrotherapy devices for pain management, today issued a mid-year update reflecting key steps taken to strengthen its financial position and advance core initiatives.
Official logo of Electromedical Technologies, Inc. (OTC: EMED), a developer of FDA-cleared electrotherapy devices for pain management.
Financial and Regulatory Alignment
In 2025, has made meaningful progress in simplifying its capital structure and positioning the Company for sustainable growth. The Company finalized an agreement with its largest convertible noteholder to retire their position, thereby reducing potential dilution and streamlining the cap table. In addition, management has initiated settlement discussions with remaining to further improve financial flexibility.
To focus internal resources during this restructuring phase, the Company filed a Form 15 with the U.S. Securities and Exchange Commission (SEC), voluntarily suspending its reporting obligations under the Exchange Act. This move allows Electromedical to maintain compliance with OTC Markets and preserve its 15c2-11 quotation status, while concentrating on internal realignment. The Company intends to meet the necessary requirements to resume full SEC reporting within the allowed timeframe and is working closely with its financial and legal advisors to achieve that goal.
Strategic Progress and Upcoming Announcements
Over the coming weeks, Electromedical expects to release a series of important updates, including:
Expanded efforts related to financial restructuring
Appointment of new board members and strategic advisors
New distribution agreements in both healthcare and consumer sectors
Signed preliminary purchase orders from wellness-sector organizations, representing initial commitments to purchase-subject to fulfillment and standard payment terms
Updated production and delivery timelines for the device
Broadened partnerships with industry-aligned organizations and strategic networks
These milestones reflect Electromedical's commitment to responsible scaling and delivering innovative, non-invasive pain management solutions to a growing market in need.
A Message from Founder and CEO, Matthew Wolfson
"Taking an idea and turning it into something real and meaningful takes years of persistence, risk, and relentless problem-solving. Being a public company doesn't make that journey easier-it adds another layer of responsibility and pressure. I'm incredibly grateful for the thousands of doctors, customers, and supporters who believe in what we're doing, have stood with us for over two decades, and continue to stand with us. There's nothing more rewarding than delivering a product that truly changes lives and helps people Feel Good Again™."
About Electromedical Technologies
Electromedical Technologies, Inc. develops and manufactures FDA-cleared electrotherapy devices designed for pain management. Its flagship product, the WellnessPro Plus™, provides safe, non-invasive therapy intended to help individuals manage chronic and acute pain without drugs or invasive procedures.
For more information, visit:
No Offer or Solicitation
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995.
All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements.
All forward-looking statements involve risks, uncertainties, and contingencies-many of which are beyond our control-that may cause actual results, performance, or achievements to differ materially from those anticipated. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at . We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Electromedical Technologies, Inc.
16413 N 91st Street, Unit C140
Scottsdale, AZ 85260
Phone: 888-880-7888
Email: [email protected]
Website:
Contact Information
Cristina Clubb
Electromedical Technologies, Inc.
[email protected]
SOURCE: Electromedical Technologies, Inc.
View the original on ACCESS Newswire
FAQ
What restructuring changes did Electromedical Technologies (EMED) announce in August 2025?
Why did Electromedical Technologies (EMED) suspend its SEC reporting?
What are the upcoming announcements expected from Electromedical Technologies (EMED)?
How is Electromedical Technologies (EMED) addressing its financial structure?
What products does Electromedical Technologies (EMED) develop?
